Retrospective study of phentermine and topiramate in a United States claims database
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Phentermine (Primary) ; Phentermine/topiramate (Primary) ; Topiramate (Primary)
- Indications Obesity
- Focus Adverse reactions
- 26 Feb 2019 According to a VIVUS media release, data from this study were published in The Journal of Clinical Endocrinology & Metabolism.
- 14 Jan 2019 According to a VIVUS media release, the company plans to include the findings from this study in the ongoing discussions with the U.S. Food and Drug Administration related to the requested label modification for Qsymia. The requested modification would allow for the safe and effective short-term use of Qsymia and could potentially reduce or modify the need for a cardiovascular outcomes study.
- 14 Jan 2019 According to a VIVUS media release, new findings from this study will be published in the February 1, 2019 issue of The Journal of Clinical Endocrinology & Metabolism and are currently available online.